In last trading session, Kyverna Therapeutics Inc (NASDAQ:KYTX) saw 0.65 million shares changing hands with its beta currently measuring 2.07. Company’s recent per share price level of $2.32 trading at $0.14 or 6.42% at ring of the bell on the day assigns it a market valuation of $100.27M. That closing price of KYTX’s stock is at a discount of -635.34% from its 52-week high price of $17.06 and is indicating a premium of 23.28% from its 52-week low price of $1.78. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.23 million shares which gives us an average trading volume of 266.76K if we extend that period to 3-months.
For Kyverna Therapeutics Inc (KYTX), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Kyverna Therapeutics Inc (NASDAQ:KYTX) trade information
Upright in the green during last session for gaining 6.42%, in the last five days KYTX remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $2.32 price level, adding 3.73% to its value on the day. Kyverna Therapeutics Inc’s shares saw a change of -37.97% in year-to-date performance and have moved 9.95% in past 5-day. Kyverna Therapeutics Inc (NASDAQ:KYTX) showed a performance of 26.78% in past 30-days. Number of shares sold short was 2.14 million shares which calculate 8.61 days to cover the short interests.
In 2025, company’s earnings growth rate is likely to be around -11.95% while estimates for its earnings growth in next 5 years are of -2.34%.
Kyverna Therapeutics Inc (NASDAQ:KYTX)’s Major holders
Insiders are in possession of 2.26% of company’s total shares while institution are holding 77.92 percent of that, with stock having share float percentage of 79.72%. Investors also watch the number of corporate investors in a company very closely, which is 77.92% institutions for Kyverna Therapeutics Inc that are currently holding shares of the company. VIDA VENTURES ADVISORS, LLC is the top institutional holder at KYTX for having 4.52 million shares of worth $33.93 million. And as of 2024-06-30, it was holding 10.4901 of the company’s outstanding shares.
The second largest institutional holder is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, which was holding about 3.37 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.8106 of outstanding shares, having a total worth of $25.26 million.
On the other hand, JPMorgan Trust II-JPMorgan Small Cap Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.0 shares of worth $2.33 million or 2.32% of the total outstanding shares. The later fund manager was in possession of 806.42 shares on Dec 31, 2024 , making its stake of worth around $1.87 million in the company or a holder of 1.87% of company’s stock.
